Joseph J. Romano

发表

NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles.

Menghang Xia, Bohumil Bednar, Kenneth D Anderson, 2004, Journal of medicinal chemistry.

Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.

M. Katharine Holloway, M. Rudd, M. Holloway, 2008, Journal of the American Chemical Society.

Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors.

M. Rudd, P. Coleman, J. Vacca, 2014, ACS medicinal chemistry letters.

Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor.

M. Rudd, P. Coleman, S. Harper, 2012, ACS medicinal chemistry letters.

Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.

M. Rudd, D. Graham, M. Holloway, 2010, Journal of medicinal chemistry.

Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure.

M. Rudd, D. Graham, M. Holloway, 2011, ACS medicinal chemistry letters.

Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.

M. Rudd, J. Vacca, N. Liverton, 2008, Angewandte Chemie.

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[ d]thiazol-5-ylamino)-6-( tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.

J. Bertin, K. Erhard, M. Convery, 2019, Journal of medicinal chemistry.

Synthesis of (S)-3-amino-benzo[b][1,4]oxazepin-4-one via Mitsunobu and SNAr reaction for a first-in-class RIP1 kinase inhibitor GSK2982772 in clinical trials

P. A. Harris, J. U. Jeong, Xiaoyang Dong, 2017 .

Design of amidobenzimidazole STING receptor agonists with systemic activity

Joseph P. Romano, J. Bertin, J. Adams, 2018, Nature.

Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.

Qian Huang, Adam T. Gates, M. Rudd, 2012, Bioorganic & medicinal chemistry letters.

P2‐Quinazolinones and Bis‐Macrocycles as New Templates for Next‐Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK‐2748 and MK‐6325

Qian Huang, Adam T. Gates, M. Rudd, 2015, ChemMedChem.

Novel applications of carbon dioxide/MeOH for the synthesis of hydantoins and cyclic ureas via the Ugi reaction

C. Hulme, R. Labaudinière, J. Salvino, 2000 .

Remarkable three-step-one-pot solution phase preparation of novel imidazolines utilizing a UDC (Ugi/de-Boc/cyclize) strategy

C. Hulme, Joseph J. Romano, Liang Ma, 1999 .

The synthetic preparation of naturally-occurring aromatase inhibitors, morachalcone A, isogemichalcone B, and isogemichalcone C

Joseph J. Romano, E. Casillas, Kristina M. Pannone, 2013 .

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.

J. Bertin, K. Erhard, D. Lipshutz, 2019 .

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

J. Bertin, M. Convery, D. Lipshutz, 2018, ACS medicinal chemistry letters.

Design of amidobenzimidazole STING receptor agonists with systemic activity

J. Bertin, J. Adams, M. Bantscheff, 2018, Nature.

Novel applications of convertible isonitriles for the synthesis of mono and bicyclic γ-lactams via a UDC strategy

C. Hulme, R. Labaudinière, J. Salvino, 2000 .

Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.

M. Rudd, D. Graham, J. Vacca, 2010, Journal of medicinal chemistry.

Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure.

M. Rudd, D. Graham, J. Vacca, 2011, ACS medicinal chemistry letters.

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

Carol A. Capriotti, J. Bertin, M. Convery, 2018, ACS medicinal chemistry letters.